Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Guyton

Showing results (121-130 of 161) with videos related to

Pageof 17
Sort By:
Atherosclerosis|October 9, 2018
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY programMichel Farnier, G Kees Hovingh, Gisle Langslet, et al.
Diabetes & Vascular Disease Research|May 13, 2011
Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetesJohn R Guyton, D John Betteridge, Michel Farnier, et al.
Journal of Clinical Lipidology|December 29, 2018
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trialRobert Dufour, G Kees Hovingh, John R Guyton, et al.
Diabetes, Obesity & Metabolism|June 11, 2009
Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemiaJ E Tomassini, T Mazzone, R B Goldberg, et al.
Journal of Clinical Lipidology|October 6, 2018
Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemiaG Kees Hovingh, John R Guyton, Gisle Langslet, et al.
Open Forum Infectious Diseases|June 26, 2015
Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected IndividualsSusanna Naggie, Keyur Patel, Lan-Yan Yang, et al.
Cardiovascular Drugs and Therapy|September 14, 2016
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or HigherHenry N Ginsberg, Daniel J Rader, Frederick J Raal, et al.
Diabetes Care|February 13, 2010
Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemiaRonald B Goldberg, John R Guyton, Theodore Mazzone, et al.
Journal of the American College of Cardiology|November 1, 1990
Results of coronary surgery after failed elective coronary angioplasty in patients with prior coronary surgeryW S Weintraub, C L Cohen, P E Curling, et al.
Journal of Clinical Lipidology|February 5, 2011
Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetesRuth S Weinstock, Ronald B Goldberg, John R Guyton, et al.
Pageof 17

Showing results (121-130 of 161) with videos related to

Sort By:
Pageof 17
Atherosclerosis|October 9, 2018
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY programMichel Farnier, G Kees Hovingh, Gisle Langslet, et al.
Diabetes & Vascular Disease Research|May 13, 2011
Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetesJohn R Guyton, D John Betteridge, Michel Farnier, et al.
Journal of Clinical Lipidology|December 29, 2018
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trialRobert Dufour, G Kees Hovingh, John R Guyton, et al.
Diabetes, Obesity & Metabolism|June 11, 2009
Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemiaJ E Tomassini, T Mazzone, R B Goldberg, et al.
Journal of Clinical Lipidology|October 6, 2018
Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemiaG Kees Hovingh, John R Guyton, Gisle Langslet, et al.
Open Forum Infectious Diseases|June 26, 2015
Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected IndividualsSusanna Naggie, Keyur Patel, Lan-Yan Yang, et al.
Cardiovascular Drugs and Therapy|September 14, 2016
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or HigherHenry N Ginsberg, Daniel J Rader, Frederick J Raal, et al.
Diabetes Care|February 13, 2010
Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemiaRonald B Goldberg, John R Guyton, Theodore Mazzone, et al.
Journal of the American College of Cardiology|November 1, 1990
Results of coronary surgery after failed elective coronary angioplasty in patients with prior coronary surgeryW S Weintraub, C L Cohen, P E Curling, et al.
Journal of Clinical Lipidology|February 5, 2011
Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetesRuth S Weinstock, Ronald B Goldberg, John R Guyton, et al.
Pageof 17